Replies to post #559793 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

I've read everything repeatedly. The omissions in the JAMA Oncology publication are clear. No FDA partial hold issue identified, no discussion of the confounded nOS data from multiple dosing, no detailing of the statistically manipulated nOS endpoint data to try to compensate for the confounding (buried in the SAP). Try reading it.